Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

1331 publications found

  1. UW Center for Community-Engaged Drug Education, Epidemiology & Research (CEDEER), Banta-Green CJ. Washington State Drug Brief: BTMPS – A New Substance Found in Community Drug Checking Samples. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, September 2024
  2. Winstead T, Singh S, Floyd A, Banta-Green C. Contingency Management for Methamphetamine Use: Qualitative Interviews at Harm Reduction Programs. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, March 2024
  3. Green TC, Silcox J, Boliver D, Gray M, Floyd AS, Irwin AN, Hansen RN, Hartung DM, Bratberg J. Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains. Journal of the American Pharmacists Association 2024;64(1):71-78. [doi: 10.1016/j.japh.2023.10.014] PMID: 37863398 PMCID: PMC11014459
  4. Carlini BH, Kellum LB, Garrett SB, Nims LN. Threaten, distract, and discredit: Cannabis industry rhetoric to defeat regulation of high-THC cannabis products in Washington State, USA. Journal of Studies on Alcohol and Drugs 2024;85(3):322-329. [doi: 10.15288/jsad.23-00277] PMID: 38270913 PMCID: PMC11218453
  5. LoParco CR, Cui Y, McCready D, Romm KF, Yang TY, Rossheim ME, Carlini B, Vinson K, Cavazos-Rehg P, Berg CJ. State requirements for non-medical US cannabis retail personnel. Journal of Public Health Management and Practice 2024;30(4):517-525. [doi: 10.1097/PHH.0000000000001892] PMID: 38833682
  6. Frank ND, Banta-Green CJ, Guthrie BL, Kingston S, Tinsley J, Whiteside L, Glick SN. Emergency room utilization and methamphetamine overdose symptoms among syringe services program participants in Washington State. Substance Use & Misuse 2024;59(7):1012-1019. [doi: 10.1080/10826084.2024.2317148] PMID: 38369494
  7. Heidari O, Banta-Green CJ. Expanding access to medications for opioid use disorder: Federal policy is only a part of the solution [editorial]. American Journal of Public Health 2024;114(7):693-695. [doi: 10.2105/AJPH.2024.307715] PMID: 38838294 PMCID: PMC11153965
  8. Douaihy A, Donovan DM, Daley DC. Twelve-step facilitation approaches. IN: Miller SC, Rosenthal RN, Levy S, Saxon AJ, Tetrault JM, Wakeman SE (eds.). THE ASAM PRINCIPLES OF ADDICTION MEDICINE (7th edition). Philadelphia: Wolters Kluwer, p. 1213-1218
  9. Allen JA, Benowitz N, Blumenthal R, Carlini BH, Cooper Z, Fong T, Halpern-Felsher B, Johnson RM, Ling P, Pacula R, Piomelli D, Silver LD, Young-Wolff K. Report and Recommendations of the High Potency Cannabis Think Tank to the State of California. Sacramento, CA: California Department of Public Health, October 2024, 42p.
  10. Irwin AN, Gray M, Ventricelli D, Boggis JS, Bratberg J, Floyd AS, Silcox J, Hartung DM, Green TC. “I go out of my way to give them an extra smile now:” A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials. Research in Social and Administrative Pharmacy 2024;20(5):512-519. [doi: 10.1016/j.sapharm.2024.02.001] PMID: 38395644 PMCID: PMC10981567
  11. Blough MJ, Rocha A, Bratberg J, Silcox J, Bolivar D, Floyd AS, Gray M, Green TC. The cost of safe injection: Insights on nonprescription syringe price variability from systematic secret shopping. Substance Use & Addiction Journal 2024;45(2):201-210. [doi: 10.1177/29767342231217831] PMID: 38258818
  12. Douaihy A, Daley DC, Donovan DM. Relapse prevention: Clinical models and intervention strategies. IN: Miller SC, Rosenthal RN, Levy S, Saxon AJ, Tetrault JM, Wakeman SE (eds.). THE ASAM PRINCIPLES OF ADDICTION MEDICINE (7th edition). Philadelphia: Wolters Kluwer, p. 1219-1235
  13. Carpenter KM, Walker DD, Mullis K, Berlin HM, Short E, Javitz HS, Carlini BH. Testing a brief quitline intervention for tobacco cannabis co-users: A randomized controlled pilot study. Tobacco Use Insights 2024;17:117917x241261302. [doi: 10.1177/1179173X241261302] PMID: 38873657 PMCID: PMC11171437
  14. Hatch MA, Laschober TC, Paschen-Wolff M, Ertl MM, Nelson CM, Wright L, Lancaster C, Feaster DJ, Forrest D, Hankey C, Monger M, Fegley JP, Irving R, Young C, Rose J, Spector A, Dresser L, Moran L, Jelstrom E, Tross S. PrEP for people who use opioids: A NIDA Clinical Trials Network survey study in Southern U.S. cities where HIV incidence is high. Drug and Alcohol Dependence 2024;257:111133. [doi: 10.1016/j.drugalcdep.2024.111133] PMID: 38447393 PMCID: PMC11131129
  15. Floyd AS, Silcox J, Strickler G, Nong T, Blough M, Bolivar D, Rabin M, Bratberg J, Irwin AN, Hartung DM, Hansen RN, Bohler R, Green TC. Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews. Drug and Alcohol Dependence Rep 2024;11:100243. [doi: 10.1016/j.dadr.2024.100243]
  16. Pusnik A, Hartzler B, Vjorn O, Rutkowski BA, Chaple M, Becker S, Freese T, Nichols M, Molfenter T. Comparison of use rates of telehealth services for substance use disorder during and following COVID-19 safety distancing recommendations: Two cross-sectional surveys. JMIR Mental Health 2024;11:e52363. [doi: 10.2196/52363] PMID: 39136186 PMCID: PMC11331268
  17. Fockele CE, Morse SC, van Draanen J, Leyde S, Banta-Green C, Huynh LN, Zatzick A, Whiteside LK. “That line that just kept moving”: Motivations and experiences of people who use methamphetamine. West J Emerg Med 2023;24(2):218-227. [doi: 10.5811/westjem.2022.12.58396] PMID: 36976607 PMCID: PMC10047723
  18. Carlini B, Garrett S, Kellum L, Nims L. Cannabis Research Report, 2021-2023. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, August 2023
  19. Kingston S, Biamont B, Banta-Green C. Community Drug Checking Network. The Use and Impact of Community Drug Checking Services. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, November 2023
  20. Irwin AN, Bratberg J, Al-Jammali Z, Arnold J, Gray M, Floyd AS, Boliver D, Hansen R, Hartun DM, Green TC. Implementation of an academic detailing intervention to increase naloxone distribution and foster engagement in harm reduction from the community clinician. Journal of the American Pharmacists Association 2023;63(1):284-294.e1. [doi: 10.1016/j.japh.2022.12.001] PMID: 36567216 PMCID: PMC9933140